Acknowledgements
ONCOLOGY
The authors thank the participating patients and their families and the study centers and investigators for their contributions to the study. The authors also thank Mengmeng Tang, Xin Zhang, Yue Wang and Yipeng Zhang for their assistance in data collection and sample checking. This trial was supported by Funding for Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University (2022-YXZX-ZL-01) and Beijing Xisike Clinical Oncology Research Foundation (Y-Young2023-019). All investigators received no remuneration. Innovent Biologics (Suzhou) Co., Ltd. provided sintilimab but had no role in the study design or writing of the manuscript.